{"id":"E02","lang":"en","question":"What drugs are in PharmaEssentia’s pipeline besides BESREMi?","answer":[{"text":"PharmaEssentia’s published early-stage pipeline lists anti-PD-1 P1801 for solid tumors and PEG-GCSF P2203 for neutropenia.","fact_ids":["f1","f2"]},{"text":"The same pipeline also lists TCR-T for solid tumors and PEG-cytokines, including IL-2, for solid tumors and immunology.","fact_ids":["f3","f4"]},{"text":"Other listed programs include novel checkpoint antibodies for solid and hematologic tumors, a bispecific immunocytokine for solid tumors, and P1101 plus anti-PD-1 for HCC.","fact_ids":["f5","f6","f7"]}],"facts":[{"id":"f1","claim":"Anti-PD-1 candidate","value":"P1801; solid tumors","as_of":"2026-10-22","source":"https://us.pharmaessentia.com/innovation/technology/","quote":"anti PD-1 (P1801)"},{"id":"f2","claim":"PEG-GCSF candidate","value":"P2203; neutropenia","as_of":"2026-10-22","source":"https://us.pharmaessentia.com/innovation/technology/","quote":"PEG-GCSF (P2203)"},{"id":"f3","claim":"Cell therapy candidate","value":"TCR-T; solid tumors","as_of":"2026-10-22","source":"https://us.pharmaessentia.com/innovation/technology/","quote":"TCR-T"},{"id":"f4","claim":"Cytokine candidates","value":"PEG-cytokines, including IL-2; solid tumors and immunology","as_of":"2026-10-22","source":"https://us.pharmaessentia.com/innovation/technology/","quote":"PEG-cytokines (e.g., IL-2)"},{"id":"f5","claim":"Checkpoint antibodies","value":"Novel checkpoint antibodies; solid and hematologic tumors","as_of":"2026-10-22","source":"https://us.pharmaessentia.com/innovation/technology/","quote":"Novel checkpoint Abs"},{"id":"f6","claim":"Bispecific immunocytokine","value":"Solid tumors","as_of":"2026-10-22","source":"https://us.pharmaessentia.com/innovation/technology/","quote":"Immunocytokine"},{"id":"f7","claim":"Combination program","value":"P1101 plus anti-PD-1; HCC","as_of":"2026-10-22","source":"https://us.pharmaessentia.com/innovation/technology/","quote":"P1101"}],"undisclosed":{"text":"The checked public pipeline does not provide an exact next readout or approval date for these early-stage programs.","source":"https://us.pharmaessentia.com/innovation/technology/","as_of":"2026-10-22","quote":"Robust Early-Stage Pipeline","scope":"Only the specific primary documents cited in this card were checked; absence is not a claim about all public disclosures."},"verified_at":"2026-10-22","coverage":"answered","limitations":["Program identities and indications are verified; no stage is inferred from flattened graphical progress bars."]}